Innospec Inc.
IOSPBasic MaterialsNASDAQSpecialty Chemicals · Last scanned Oct 24, 2026
Scan Results
Daily timeframeInnospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. With a market capitalization of $2.43B, it sits in mid-cap territory. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services.
Market Cap
$2.43B
Beta
0.89
P/E (TTM)
20.13
P/E (Fwd)
16.00
EPS (TTM)
$4.90
EPS (Fwd)
$6.17
ROE
9.1%
ROA
5.1%
Cash
$250.2M
Total Debt
$47.9M
Free CF
$32.6M
52W Change
29.3%
Annual Financials
Cash vs Debt
Where IOSP stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, IOSP finished 16.43% above its 150-day moving average ($83.68) and 17.91% above its 200-day moving average ($82.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IOSP overbought or oversold?
At the October 14, 2026 close, IOSP's RSI(14) was 52.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Innospec Inc. holds $250.2M in cash against $47.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $32.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 9.1%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.96B (2022) to $1.78B (2025).
With cash comfortably exceeding debt, IOSP has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Innospec Inc.'s trajectory.